

10. Callaghan BC, Reynolds E, Banerjee M, Kerber KA, Skolarus LE, Burke JF. Longitudinal pattern of pain medication utilization in peripheral neuropathy patients. *Pain* 2019;160:592-599.
11. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *Jama* 2016;315:1624-1645.
12. Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. *Neurology* 2014;83:1277-1284.
13. Kuehn BM. Accelerated overdose deaths linked with COVID-19. *JAMA* 2021;325:523.
14. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology* 2011;76:1758-1765.
15. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. *Lancet Neurol* 2015;14:162-173.
16. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *European Journal of Neurology* 2010;17:1113-1123.
17. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. *Neurology*;88:1958-1967.
18. Gronseth GS, Cox J, Gloss D, et al. Clinical Practice Guideline Process Manual. Minneapolis, MN: The American Academy of Neurology; 2017.
19. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial. *Jama* 1998;280:1831-1836.
20. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. *New England Journal of Medicine* 2005;352:1324-1334.